Cardiac and renal effects of atrasentan in combination with enalapril and paricalcitol in uremic rats

Kidney and Blood Pressure Research

Volumn 39, Issue 4, 2014, Pages 340-352

  Ritter, Cynthia ^a   Zhang, Sarah ^a   Finch, Jane L ^a   Liapis, Helen ^a   Suarez, Edu ^b,c   Ferder, Leon ^b   Delmez, James ^a   Slatopolsky, Eduardo ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^c University of Puerto Rico at Ponce   (Puerto Rico)

Author keywords

ACE inhibitor; Endothelin 1 receptor A; Renal failure; Uremic rats; VDRA; Vitamin D

Indexed keywords

ATRASENTAN; CREATININE; ENALAPRIL; PARICALCITOL; BONE DENSITY CONSERVATION AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ERGOCALCIFEROL; PYRROLIDINE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR PARAMETERS; CELL SIZE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; FEMALE; HEART MUSCLE CELL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; NEPHRECTOMY; NONHUMAN; PROTEINURIA; RAT; RENAL SYSTEM EFFECT; RENAL SYSTEM PARAMETERS; SYSTOLIC BLOOD PRESSURE; UREMIA; VASCULAR FIBROSIS; ANIMAL; DRUG COMBINATION; DRUG EFFECTS; FOCAL GLOMERULOSCLEROSIS; HEART; HEART MUSCLE; KIDNEY; KIDNEY FUNCTION TEST; NEPHRITIS; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; SURVIVAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BONE DENSITY CONSERVATION AGENTS; DRUG THERAPY, COMBINATION; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONISTS; ERGOCALCIFEROLS; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEART; KIDNEY; KIDNEY FUNCTION TESTS; MYOCARDIUM; NEPHRECTOMY; NEPHRITIS; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; SURVIVAL ANALYSIS; UREMIA;

EID: 84910653923     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000355811     Document Type: Article

References (37)

1. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9:S16-23.
2. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985;76:612-619.
3. Brewster UC, Setaro JF, Perazella MA: The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003;326:15-24.
4. Kamper AL, Strandgaard S, Leyssac PP: Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 1992;5:423-430.
5. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006;354:131-140.
6. Tan X, Li Y, Liu Y: Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006;17:3382-3393.
7. Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, Slatopolsky E: Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007;18:1796-1806.
8. Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz U, Ritz E, Amann K: 1, 25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004;286:F526-F533.
9. Makibayashi K, Tatematsu M, Hirata M, Fukushima N, Kusano K, Ohashi S, Abe H, Kuze K, Fukatsu A, Kita T, Doi T: A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 2001;158:1733-1741.
10. Panichi V, Migliori M, Taccola D, Filippi C, De Nisco L, Giovannini L, Palla R, Tetta C, Camussi G: Effects of 1, 25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int 2001;60:87-95.
11. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E: Effect of 1, 25(Oh)(2) Vitamin D-3 On Glomerulosclerosis in Subtotally Nephrectomized Rats. Kidney Int 1998;53:1696-1705.
12. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus M, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-456.
13. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG, Medical Directors of Dialysis Clinic I: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006;70:1858-1865.
14. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W: Independent association of low serum 25-hydroxyvitamin d and 1, 25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008;168:1340-1349.
15. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R: Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008;52:249-255.
16. Zehnder D, Quinkler M, Eardley KS, Bland R, Lepenies J, Hughes SV, Raymond NT, Howie AJ, Cockwell P, Stewart PM, Hewison M: Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int 2008;74:1343-1353.
17. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D: Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010;376:1543-1551.
18. Husain K, Ferder L, Mizobuchi M, Finch J, Slatopolsky E: Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am J Nephrol 2009;29:465-472.
19. Finch JL, Suarez EB, Husain K, Ferder L, Cardema MC, Glenn DJ, Gardner DG, Liapis H, Slatopolsky E: Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats. Am J Physiol Renal Physiol 2012;302:F141-F149.
20. Gagliardini E, Buelli S, Benigni A: Endothelin in chronic proteinuric kidney disease. Contrib Nephrol 2011;172:171-184.
21. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL: Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011;22:763-772.
22. Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM: Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes. Diabetologia 2011;54:979-988.
23. Wolkart G, Pang X, Stessel H, Kirchengast M, Brunner F: Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats. Br J Pharmacol 2007;151:1187-1197.
24. Wolkart G, Stessel H, Saad Z, Kirchengast M, Brunner F: Cardioprotective effects of atrasentan, an endothelin-A receptor antagonist, but not of nitric oxide in diabetic mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Br J Pharmacol 2006;148:671-681.
25. Vaneckova I, Kujal P, Huskova Z, Vanourkova Z, Vernerova Z, Certikova Chabova V, Skaroupkova P, Kramer HJ, Tesar V, Cervenka L: Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats. Kidney Blood Press Res 2012;35:382-392.
26. Nasser SA, Elmallah AI, Sabra R, Khedr MM, El-Din MM, El-Mas MM: Blockade of endothelin ET, but not thromboxane, receptors offsets the cyclosporine-evoked hypertension and interrelated baroreflex and vascular dysfunctions. Eur J Pharmacol 2014;727C:52-59.
27. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E: Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007;72:709-715.
28. Nakamura H, Tokumoto M, Mizobuchi M, Ritter CS, Finch JL, Mukai M, Slatopolsky E: Novel markers of left ventricular hypertrophy in uremia. Am J Nephrol 2010;31:292-302.
29. Mizobuchi M, Nakamura H, Tokumoto M, Finch J, Morrissey J, Liapis H, Slatopolsky E: Myocardial effects of VDR activators in renal failure. J Steroid Biochem Mol Biol 2010;121:188-192.
30. Panizo S, Barrio-Vazquez S, Naves-Diaz M, Carrillo-Lopez N, Rodriguez I, Fernandez-Vazquez A, Valdivielso JM, Thadhani R, Cannata-Andia JB: Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis. Nephrol Dial Transplant 2013;28:2735-2744.
31. Lee SB, Kalluri R: Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl 2010;119:S22-S26.
32. Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 2005;115:209-218.
33. Dhaun N, Melville V, Blackwell S, Talwar DK, Johnston NR, Goddard J, Webb DJ: Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. J Am Soc Nephrol 2013;24:31-36.
34. Zoja C, Cattaneo S, Fiordaliso F, Lionetti V, Zambelli V, Salio M, Corna D, Pagani C, Rottoli D, Bisighini C, Remuzzi G, Benigni A: Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. Am J Physiol Renal Physiol 2011;301:F1114-1123.
35. Jesmin S, Zaedi S, Shimojo N, Iemitsu M, Masuzawa K, Yamaguchi N, Mowa CN, Maeda S, Hattori Y, Miyauchi T: Endothelin antagonism normalizes VEGF signaling and cardiac function in STZ-induced diabetic rat hearts. Am J Physiol Endocrinol Metab 2007;292:E1030-E1040.
36. Reriani M, Raichlin E, Prasad A, Mathew V, Pumper GM, Nelson RE, Lennon R, Rihal C, Lerman LO, Lerman A: Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation 2010;122:958-966.
37. Yoon MH, Reriani M, Mario G, Rihal C, Gulati R, Lennon R, Tilford JM, Lerman LO, Lerman A: Longterm endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis. Int J Cardiol 2013;168:1316-1321.